Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2026-03-07 @ 11:03 PM
Study NCT ID:
NCT02078960
Status:
TERMINATED
Last Update Posted:
2021-11-09
First Post:
2014-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-10-09
Start Date Type:
ACTUAL
Primary Completion Date:
2017-07-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-11-27
Completion Date Type:
ACTUAL
First Submit Date:
2014-02-28
First Submit QC Date:
None
Study First Post Date:
2014-03-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-19
Results First Submit QC Date:
None
Results First Post Date:
2019-01-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-06
Last Update Post Date:
2021-11-09
Last Update Post Date Type:
ACTUAL